HYDROXYZINE PAMOATE

Post-LOE

hydroxyzine pamoate

R-Pharm US

ANDAORALCAPSULE

Approved

Jan 1987

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

HYDROXYZINE PAMOATE (hydroxyzine pamoate) by R-Pharm US is clinical pharmacology hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Approved for anxiety. First approved in 1987.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine pamoate is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the…

Indications (1)

anxiety

Worked on HYDROXYZINE PAMOATE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.